Abstract:ABSTRACTThe interaction between Receptor Activator of NF‐κB Ligand (RANKL) and its receptor RANK is essential for the differentiation and bone resorbing capacity of the osteoclast. Osteoprotegerin (OPG), a soluble homodimer, acts as a decoy receptor for RANKL and thus inhibits osteoclastogenesis. An imbalance in the RANKL/RANK/OPG axis, with decreased OPG and/or increased RANKL, is associated with diseases that favor bone loss, including osteoporosis. Recently, we established a yeast surface display system and screened libraries of randomly mutated RANKL proteins to identify mutations that abolish binding to OPG while preserving recognition of RANK. These efforts yielded several RANKL variants possessing substantially higher affinity for RANK compared to their wild‐type (WT) counterpart. Using recombinant RANKL mutant proteins, we find those with increased affinity for RANK produce more robust signaling in osteoclast lineage cells and have greater osteoclastogenic potential. Our results are the first to document gain of function RANKL mutations. They indicate that the physiological RANKL/RANK interaction is not optimized for maximal signaling and function, perhaps reflecting the need to maintain receptor specificity within the tumor necrosis factor superfamily (TNFSF). Instead, we find, a biphasic relationship exists between RANKL/RANK affinity and osteoclastogenic capacity. In our panel of RANKL variants, this relationship is driven entirely by manipulation of the kinetic off‐rate. Our structure‐based and yeast surface display‐derived insights into manipulating this critical signaling axis may aid in the design of novel anti‐resorptive therapies as well as provide a paradigm for design of other receptor‐specific TNF superfamily ligand variants. J. Cell. Biochem. 116: 2476–2483, 2015. © 2015 Wiley Periodicals, Inc.

LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption

Role of OPG/RANKL/RANK system during alveolar bone resorption and remodeling

Isoalantolactone Inhibits RANKL-induced Osteoclast Formation Via Multiple Signaling Pathways

Lrp4 In Osteoblasts Suppresses Bone Formation And Promotes Osteoclastogenesis And Bone Resorption

Lgr4 promotes aerobic glycolysis and differentiation in osteoblasts via the canonical Wnt/β ‐catenin pathway

LGR4: A New Receptor Member in Endocrine and Metabolic Diseases

Inhibiting Monoacylglycerol Lipase Suppresses RANKL-Induced Osteoclastogenesis and Alleviates Ovariectomy-Induced Bone Loss

LncRNA AK077216 promotes RANKL‐induced osteoclastogenesis and bone resorption via NFATc1 by inhibition of NIP45

A Novel Role for RILP in Regulating Osteoclastogenesis and Bone Resorption

RANKL Downregulates Cell Surface CXCR6 Expression Through JAK2/STAT3 Signaling Pathway During Osteoclastogenesis

Low-intensity Pulsed Ultrasound Inhibits RANKL-induced Osteoclast Formation Via Modulating ERK-c-Fos-NFATc1 Signaling Cascades.

LGR6 promotes osteogenesis by activating the Wnt/β-catenin signaling pathway

RhoA Promotes Osteoclastogenesis and Regulates Bone Remodeling Through Mtor-Nfatc1 Signaling.

LRP8 mediates Wnt/β-catenin signaling and controls osteoblast differentiation.

RANKL from bone marrow adipose lineage cells promotes osteoclast formation and bone loss

Correlating Rank Ligand/Rank Binding Kinetics with Osteoclast Formation and Function

Phospholipase C β4 promotes RANKL-dependent osteoclastogenesis by interacting with MKK3 and p38 MAPK

Bone marrow adipogenic lineage precursors are the major regulator of bone resorption in adult mice

FOXO1 Mediates RANKL-induced Osteoclast Formation and Activity.

Lactate dehydrogenase A inhibition prevents RANKL-induced osteoclastogenesis by reducing enhanced glycolysis

Coupling of bone resorption and formation by RANKL reverse signalling